Enzolytics Announces The Signing Of The Business Combination Agreement With Sagaliam Acquisition Corp
Enzolytics Announces The Signing Of The Business Combination Agreement With Sagaliam Acquisition Corp
Enzolytics, Inc. (OTC:ENZC) (
Enzolytics, Inc.（場外交易代碼：ENZC）(
Enzolytics, Inc. announces today that it has executed the binding business combination agreement for the sale of Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO"), the operating subsidiaries of Enzolytics Inc., to Sagaliam Acquisition Corp (NASDAQ:SAGA) in a transaction valued at $450,000,000. The combined company is expected to trade on NASDAQ. The entities have begun the de-SPAC process and are moving on with the closing of this project.
Enzolytics, Inc.今天宣佈，它已執行具有約束力的業務合併協議，將Enzolytics Inc. 的運營子公司Biogenysis, Inc.（“BGEN”）和Virogentics Inc.（“VIRO”）出售給Sagaliam收購公司（納斯達克股票代碼：SAGA），交易價值4.5億美元。合併後的公司預計將在納斯達克上市。這些實體已經開始了de-SPAC進程，並正在推進該項目的結束。
Harry Zhabilov, CSO of VIRO, stated, "The SAGA transaction opens numerous opportunities to advance our existing technology, developing new technology and expansion of our growing nutraceutical product line at what we believe will be a significantly faster pace."
VIRO首席科學官Harry Zhabilov表示：“SAGA的交易爲推進我們現有技術、開發新技術和擴大我們不斷增長的營養保健品產品線開闢了許多機會，我們認爲這將大大加快步伐。”
Dr. Gaurav Chandra, CEO of BGEN, stated: "Biogenysis strives to make a significant impact in drug discovery and development by utilizing advanced AI technology. Our focus is on safeguarding our assets with multi-layered security while expanding our IP portfolio to include AI-driven monoclonal antibodies. With these antibodies, we aim to revolutionize the fight against HIV, COVID-19 mutations, and other viruses. Collaborating with pharmaceutical companies, our focus is to cover all viruses in our repository, providing patients with necessary diagnostics and therapies. Our AI Platform is constantly evolving with disruptive innovations in healthcare. We are proud to be at the forefront of this crucial work and look forward to continuing to positively impact the world."
BGEN首席執行官高拉夫·錢德拉博士表示：“Biogenysis努力利用先進的人工智能技術對藥物發現和開發產生重大影響。我們的重點是通過多層安全保護我們的資產，同時擴大我們的知識產權組合，將人工智能驅動的單克隆抗體包括在內。通過這些抗體，我們的目標是徹底改變對抗 HIV、COVID-19 突變和其他病毒的鬥爭。與製藥公司合作，我們的重點是覆蓋我們存儲庫中的所有病毒，爲患者提供必要的診斷和治療。隨着醫療保健領域的顛覆性創新，我們的人工智能平台不斷髮展。我們很自豪能夠站在這一關鍵工作的最前沿，並期待繼續對世界產生積極影響。”
Charles Cotropia, Enzolytics' CEO, said, "We have a well-defined strategy and the necessary technology in place for producing numerous therapeutics for successfully treating numerous viruses that affect patients around the world. Completing the business combination with Sagaliam comes at a critical time. By providing additional funding to Biogenysis and Virogentics, this combination will make possible the final development of the numerous therapeutics now being produced."
Enzolytics首席執行官Charles Cotropia表示：“我們有明確的戰略和必要的技術，可以生產多種療法，成功治療影響世界各地患者的多種病毒。完成與Sagaliam的業務合併正值關鍵時刻。通過向Biogenysis和Virogentics提供額外資金，這種組合將使目前正在生產的衆多療法的最終開發成爲可能。”
Barry Kostiner, the CEO of Sagaliam, stated, "Being listed on Nasdaq provides increased visibility and access to a broader pool of investors, facilitating the advance of our pioneering research and drug development initiatives. Bringing Virogentics and Biogenysis to our Nasdaq platform opens the door to funding which serves as the lifeblood of all pharmaceutical development companies. We are working with the investor community, as well as the dedicated VIRO and BGEN management teams, to secure the financial resources required to expedite clinical trials. With these investments, we aim to accelerate our progress, ensuring that both therapeutic and nutraceutical innovations swiftly find their way into the market, ultimately improving the lives of countless individuals."
Sagaliam首席執行官巴里·科斯蒂納表示：“在納斯達克上市可以提高知名度，接觸更廣泛的投資者，從而促進我們開創性的研究和藥物開發計劃的推進。將Virogentics和Biogenysis引入我們的納斯達克平台爲融資打開了大門，而融資是所有制藥開發公司的命脈。我們正在與投資者羣體以及專門的VIRO和BGEN管理團隊合作，以確保加快臨床試驗所需的財務資源。通過這些投資，我們的目標是加快進展，確保治療和營養保健品的創新都能迅速進入市場，最終改善無數人的生活。”
譯文內容由第三人軟體翻譯。